🚀 VC round data is live in beta, check it out!
Gabather Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gabather and similar public comparables like China SXT Pharmaceuticals, Biophytis, Clearside Biomedical, Biosenic and more.
Gabather Overview
About Gabather
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.
Founded
2014
HQ
Employees
3
Website
Sectors
Financials (LTM)
EV
$2M
Gabather Financials
Gabather reported last 12-month revenue of — and negative EBITDA of ($783K).
In the same LTM period, Gabather generated — in gross profit, ($783K) in EBITDA losses, and had net loss of ($794K).
Revenue (LTM)
Gabather P&L
In the most recent fiscal year, Gabather reported revenue of — and EBITDA of ($488K).
Gabather expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($783K) | XXX | ($488K) | XXX | XXX | XXX |
| Net Profit | ($794K) | XXX | ($503K) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gabather Stock Performance
Gabather has current market cap of $2M, and enterprise value of $2M.
Market Cap Evolution
Gabather's stock price is $0.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $2M | 0.3% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGabather Valuation Multiples
Gabather trades at (2.1x) EV/EBITDA.
Gabather Financial Valuation Multiples
As of April 19, 2026, Gabather has market cap of $2M and EV of $2M.
Equity research analysts estimate Gabather's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gabather has a P/E ratio of (2.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV/EBITDA | (2.1x) | XXX | (3.4x) | XXX | XXX | XXX |
| EV/EBIT | (2.1x) | XXX | (3.4x) | XXX | XXX | XXX |
| P/E | (2.5x) | XXX | (4.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gabather Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gabather Margins & Growth Rates
Gabather's revenue in the last fiscal year grew by —.
Gabather's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Gabather Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 177% | XXX | 203% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gabather Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gabather | XXX | XXX | XXX | XXX | XXX | XXX |
| China SXT Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Biophytis | XXX | XXX | XXX | XXX | XXX | XXX |
| Clearside Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Biosenic | XXX | XXX | XXX | XXX | XXX | XXX |
| Aptahem | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gabather M&A Activity
Gabather acquired XXX companies to date.
Last acquisition by Gabather was on XXXXXXXX, XXXXX. Gabather acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gabather
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGabather Investment Activity
Gabather invested in XXX companies to date.
Gabather made its latest investment on XXXXXXXX, XXXXX. Gabather invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gabather
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gabather
| When was Gabather founded? | Gabather was founded in 2014. |
| Where is Gabather headquartered? | Gabather is headquartered in Sweden. |
| How many employees does Gabather have? | As of today, Gabather has over 3 employees. |
| Is Gabather publicly listed? | Yes, Gabather is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Gabather? | Gabather trades under GABA ticker. |
| When did Gabather go public? | Gabather went public in 2014. |
| Who are competitors of Gabather? | Gabather main competitors are China SXT Pharmaceuticals, Biophytis, Clearside Biomedical, Biosenic. |
| What is the current market cap of Gabather? | Gabather's current market cap is $2M. |
| Is Gabather profitable? | No, Gabather is not profitable. |
| What is the current EBITDA of Gabather? | Gabather has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Gabather? | Current EBITDA multiple of Gabather is (2.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.